Uncategorized
XOMA launches gevokizumab study for treatment of Behçet’s disease uveitis
XOMA announced the launch of a U.S. clinical trial to investigate the safety and efficacy of gevokizumab for the treatment of patients with Behçet’s disease uveitis, according to a press release issued by the company. The EYEGUARD-US trial will comprise up to 28 patients administered the monoclonal antibody, gevokizumab, in an open-label design. Patients who respond to gevokizumab by day 28 will be randomly assigned in a 1:1, double-masked fashion to either gevokizumab 60 mg or placebo, administered subcutaneously once monthly, according to the press release. The study’s primary endpoint (Read more...)